uniQure provides regulatory update on AMT-130 gene therapy
The update follows a meeting with the FDA regarding a path forward for the Huntington's disease treatment.
See the latest news and media coverage for uniQure. We track all announcements, press releases, and industry mentions in real time, all in one place.
Gene therapy company targeting neurological and rare diseases
uniqure.comLast updated
In short: uniQure reached an agreement with the FDA to pursue accelerated approval for its Huntington’s disease gene therapy AMT-130.
The update follows a meeting with the FDA regarding a path forward for the Huntington's disease treatment.
The company acknowledges the lack of a current treatment and thanks an article profiling Nancy Wexler.
They participated at Boston's Castle Island, raising funds for Huntington's Disease research, family services, and advocacy.
The company also highlighted recent progress across its business.
Dutch drugmaker UniQure said on Wednesday the U.S. Food and Drug Administration has agreed that data from a mid-stage ...
Qure may seek approval in the UK first while in talks with the FDA about its request for a larger, sham-controlled trial of the one-time...
Investing.com -- uniQure BV (NASDAQ:QURE) shares surged 36% Monday following reports that the head of the US Food and Drug Administration's division of vaccines and...
You have previously refused browser notifications for fd.nl. Go to browser settings and allow browser notifications for fd.nl. The exact actions depend on...
Track uniQure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to uniQure and other trending companies.